Walleye Capital
IMVT icon

Walleye Capital’s Immunovant IMVT Stock Holding History

Walleye Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Hold
5,400
– – ﹤0.01% 3481
2026
Q1 		$134K Buy
5,400
+1,300
+32% +$33.7K ﹤0.01% 3541
2025
Q4 		$104K Buy
+4,100
New +$91.4K ﹤0.01% 3850
2024
Q2 		– Sell
-8,000
Closed -$258K – 5785
2024
Q1 		$258K Sell
8,000
-100
-1% -$3.65K ﹤0.01% 3782
2023
Q4 		$341K Buy
+8,100
New +$298K ﹤0.01% 3266

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Walleye Capital's IMVT Position: Q2 2026 in Review

Walleye Capital increased its Immunovant (IMVT) stake by 143% in Q2 2026, buying an estimated $119K and bringing the position to 6,633 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

Walleye Capital first reported a position in IMVT in Q1 2021 and has held it in 12 quarters since. The position peaked at $9.48M in Q4 2022. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Walleye Capital held 6,633 shares of Immunovant worth $256K as of Q2 2026.
  • Walleye Capital bought 3,902 Immunovant shares in Q2 2026, an estimated $119K.
  • Immunovant made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3304 holding.
  • Walleye Capital first reported a position in Immunovant in Q1 2021 and has held it in 12 quarters since.
  • Walleye Capital's Immunovant position peaked at $9.48M in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.